{"i": ["statin", "HMG CoA reductase inhibitor", "capecitabine", "irinotecan , capecitabine , fluorouracil , leucovorin", "FOLFIRI / XELIRI plus simvastatin", "5 - fluorouracil or cisplatin", "chemotherapy", "cytotoxic chemotherapy , antiangiogenic therapy", "250 mg m \u2212 2 irinotecan", "simvastatin or placebo", "XELOX and bevacizumab", "bevacizumab", "statins and cytotoxic chemotherapy regimen", "FOLFIRI", "conventional FOLFIRI chemotherapy", "Simvastatin and placebo", "leucovorin", "FOLFIRI chemotherapy", "XELIRI / FOLFIRI chemotherapy plus simvastatin or XELIRI / FOLFIRI chemotherapy plus placebo", "5 % dextrose", "chemotherapy regimen ( FOLFIRI ),", "conventional chemotherapy", "5 - FU", "cetuximab", "statins", "FOLFIRI / XELIRI plus placebo .", "XELIRI / FOLFIRI plus placebo", "XELIRI / FOLFIRI", "simvastatin plus XELIRI / FOLFIRI", "placebo", "XELIRI / FOLFIRI plus simvastatin", "chemotherapy with capeciatabine , oxaliplatin , and cetuximab", "cytotoxic chemotherapy", "XELIRI / FOLFIRI chemotherapy", "oxaliplatin - containing chemotherapy", "placebo - controlled", "simvastatin", "irinotecan", "XELIRI \u00b1 simvastatin", "XELIRI or FOLFIRI chemotherapy", "XELIRI", "lovastatin", "Statins", "FOLFIRI \u00b1 simvastatin", "simvastatin to XELIRI or FOLFIRI chemotherapy"], "o": ["risk of colorectal cancer", "diarrhoea", "anaemia , nausea , anorexia , and alopecia", "PFS .", "risk reduction of cancer", "Adverse effects", "objective response rate and patient ' s clinical characteristics", "endothelial release of vascular endothelial growth factor", "median OS", "disease progression , unacceptable toxicity , or patient refusal .", "Abnormal elevations of CPK , ALT , and AST", "response rate , duration of response , overall survival ( OS ), time to progression , and toxicity .", "prevalence of metastasis", "tumour cell proliferation .", "Duration of tumour response", "response rate", "efficacy and safety", "complete blood cell count with differentials , chemistry , creatinine phophokinase ( CPK ) and LDH measurements , lipid profiling", "PFS", "endothelial apoptosis", "median PFSs", "efficacy and toxicity profile", "anaemia", "response rate , duration of tumour response , overall survival ( OS ), time to progression ( TTP ), and safety profile .", "liver metastasis", "median TTP", "DCR ( disease control rate )", "chest X - ray", "OS , PFS , and TTP , survival functions", "antiangiogenic effects", "aspartate aminotransferase ( AST ),", "ORR ( overall response rate )", "PFS or OS", "delivered relative dose intensities", "computed tomography ( CT ) scan of the abdomen and pelvis", "progression - free survival ( PFS ),", "neutropenia", "treatment - related toxicities .", "grade 3 or 4 increase of CPK", "presence of cervical lymph node metastasis", "apoptosis", "toxicity", "TTP", "vital signs", "all - cause mortality", "survival outcomes", "progression events", "Grade \u2a7e 3 nausea and anorexia", "median PFS", "antitumour activity", "alanine aminotransferase ( ALT", "pro - angiogenic effects", "clinical efficacy and safety", "incidence of grade \u2a7e 3 adverse events ( AEs )", "colorectal cancer - specific mortality", "OS and TTP .", "OS", "progression - free survival ( PFS ).", "proportion of patients having any grade of liver enzyme elevation"]}